Compare HCAT & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCAT | ONCY |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.9M | 112.5M |
| IPO Year | 2019 | 2002 |
| Metric | HCAT | ONCY |
|---|---|---|
| Price | $1.27 | $0.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | $2.53 | ★ $7.33 |
| AVG Volume (30 Days) | 581.9K | ★ 1.2M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $311,136,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,505.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1.48 | N/A |
| 52 Week Low | $0.96 | $0.33 |
| 52 Week High | $5.06 | $1.51 |
| Indicator | HCAT | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 39.38 |
| Support Level | $1.02 | $0.82 |
| Resistance Level | $2.41 | $1.14 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 60.78 | 10.17 |
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platform, analytics applications and support services and generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.